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Prognostic Usefulness of Eosinopenia in the Pediatric Intensive 
Care Unit
Eosinopenia, a biomarker for infection, has recently been shown to be a predictor of adult 
mortality in the intensive care unit (ICU). Our study assessed the usefulness of eosinopenia 
as a mortality and an infection biomarker in the pediatric ICU (PICU). We compared the 
PICU mortality scores, eosinophil count and percentage at ICU admission between children 
who survived and those who did not survive and between children with infection and 
those without infection. A total of 150 patients were evaluated. The initial eosinophil 
count and percentage were significantly lower in the group that did not survive when 
compared to those that did survive (P < 0.001; P < 0.001). However, there was no 
significant difference in the eosinophil count and percentage seen in patients with and 
without infection. Eosinopenia, defined as an eosinophil count < 15 cells/µL and an 
eosinophil percentage < 0.25%, (hazard ratio [HR]: 2.96; P = 0.008) along with a 
Pediatric Index of Mortality (PIM) 2 (HR: 1.03; P = 0.004) were both determined to be 
independent predictors of mortality in the PICU. The presence of eosinopenia at the ICU 
admission can be a useful biomarker for mortality in children, but is not useful as a 
biomarker for infection.
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INTRODUCTION
The prediction of mortality in the intensive care units (ICUs) is 
more intricate in children than in adults because a precise and 
complete assessment of consciousness in non-verbal children 
is limited, despite the fact that such an assessment is the most 
important factor for predicting mortality (1). Vital signs are also 
crucial factors, but they are difficult to measure precisely in chil-
dren. This is due to both the variations in normal ranges that 
are dependent upon age, weight, and height and the difficulty 
in performing invasive procedures to measure them, such as 
establishing arterial and central vein access. The difficulty in 
obtaining blood samples in children is another potential obsta-
cle to properly predicting their mortality, since most mortality 
scoring systems require broad laboratory data (2).
 There have been many trials to assess several pediatric mor-
tality scores (including the Pediatric Index of Mortality [PIM] 2) 
with satisfactory results (2-6). However, these scores still require 
an assessment of consciousness, vital signs, and numerous lab-
oratory data. Therefore, a simpler prognostic biomarker is des-
perately needed in the pediatric ICU (PICU).
 Recently, many researchers have suggested various biomark-
ers to predict the outcome in patients with critical illnesses (7, 
8). C-reactive protein (CRP), pro-calcitonin, and thrombocyto-
penia are some of the suggested biomarkers that have already 
been utilized in the clinical arena (9). Eosinopenia has also gained 
an interest as a sensitive, specific, easy-to-measure, and inex-
pensive biomarker in the adult ICU (10, 11).
 Sepsis, a systemic inflammatory response syndrome (SIRS) 
associated with infection, is strongly associated with mortality 
in the ICU (12). Acute infection can cause eosinopenia (13) 
through several mechanisms, such as peripheral sequestration 
of eosinophils in inflammatory sites, suppression of the egress 
of mature eosinophils from the bone marrow, and suppression 
of eosinophil production (14). Acute stress also involves eosin-
openia, which is mediated by adrenal glucocorticoids and epi-
nephrine. Severe, stressful conditions in the ICU are directly 
linked to mortality (15). Eosinopenia can reflect increased mor-
tality in the ICU as a result of both acute infections and severe, 
stressful conditions.
 There are few studies on eosinopenia as a mortality biomarker 
in children. Additionally, it has not yet been clarified as to wheth-
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er eosinopenia is a useful infection biomarker in children. This 
study was conducted to evaluate the usefulness of eosinopenia 
in predicting mortality and infection in the PICU.
MATERIALS AND METHODS
Study subjects and classification
We evaluated all pediatric patients admitted to the ICU of Sev-
erance Hospital, Seoul, Korea from January 2009 to March 2012. 
Patients who were discharged or died within 24 hr after ICU ad-
mission, as well as those who were treated with systemic steroids 
within one week of admission to the ICU were excluded (16). 
Infant cases and cardiac cases were treated in separate special-
ized units.
 All ICU admissions were classified into two sets of separate 
groups (survivor vs non-survivor group, non-infection vs infec-
tion group). Survivors were defined as patients who were dis-
charged from the ICU after recovery, while the patients who died 
during their ICU care were classified as non-survivors. Infection 
cases were classified according to criteria from the International 
Pediatric Sepsis Consensus Conference (17). Infection was di-
agnosed by the presence of a pathogen-proven infection (posi-
tive culture, tissue stain, or polymerase chain reaction test) or a 
clinical syndrome associated with a high probability of infection, 
such as positive findings on clinical examination, imaging, or 
laboratory tests (e.g., white blood cells [WBCs] in a normally ster-
ile body fluid, perforated viscus, chest radiograph consistent 
with pneumonia, petechial or purpuric rash, or purpura fulmi-
nans) (17).
Data collection 
All patients were evaluated in terms of their age, gender, princi-
pal diagnosis for ICU care, infection status, and infection site 
at the time of ICU admission. CRP and WBC, with neutrophil 
and eosinophil counts and percentages of total WBC, were mea-
sured. Blood samples were obtained from indwelling arterial 
catheters or by venipuncture within the first 24 hr of ICU admis-
sion. Blood samples were drawn from each patient into EDTA 
tubes and were immediately transported to the chemical labo-
ratory department at room temperature. The assays were per-
formed within one hour of blood sampling. The WBC count and 
the eosinophil count were determined using an automated an-
alyzer (ADVIA 2120 Hematology System, Siemens Healthcare 
Diagnostics, Forchheim, Germany). The plasma CRP concen-
tration was measured by direct immunoturbidimetry (CA400, 
Beckman Coulter, CA, USA). The Pediatric RISk of Mortality 
(PRISM) III, PIM 2, and Pediatric Logistic Organ Dysfunction 
(PELOD) scores were recorded in all cases (3-5).
Statistical analysis
Parametrically distributed values in the text and tables are ex-
pressed as means ± standard deviations (SDs). Non-parametri-
cally distributed values are expressed as median values with in-
ter-quartile ranges. The survivor and non-survivor groups were 
compared in terms of patient characteristics, PICU mortality 
scores, and laboratory data by Student’s t-test for continuous 
variables and the chi-square test for categorical variables (if the 
data was parametrically distributed). The non-infection and in-
fection groups were compared in the same manner as the sur-
vivor and non-survivor groups. The Mann-Whitney test was uti-
lized to analyze the non-parametrically distributed data.
 The receiver operating characteristic (ROC) curves and the 
areas under the curves (AUCs) were determined for eosinophil 
counts and eosinophil percentages at ICU admission. The best 
cutoff values for eosinophil count and eosinophil percentage 
were chosen based on the Younden’s index and the AUC. We 
calculated the sensitivity and specificity at the best cutoff points 
for the eosinophil count and eosinophil percentage, as well as 
at the point where both the eosinophil count and percentage 
were taken into account.
 According to the best cutoff point where both eosinophil count 
and percentage were taken into account, two groups of patients 
with and without eosinopenia were compared in terms of sur-
vival rate. Survival curves were determined by the Kaplan-Meier 
method and the differences in survival between the subgroups 
were analyzed using the log-rank test. We used Cox proportion-
al-hazard regression models to determine hazard ratios (HRs). 
All variables with P  values < 0.1 on univariate analysis were in-
cluded in the multivariate analysis.
 A P  value < 0.05 was considered statistically significant. The 
Statistical Package for the Social Sciences (version 18.0, SPSS 
Inc., Chicago, IL, USA) was used for all analyses.
Ethics statement
All data were collected and analyzed retrospectively in this study. 
This study was approved by the institutional review board of 
Severance Hospital (Seoul, Korea, IRB No. 4-2012-0369), and 
exempted from an informed consent form.
RESULTS
A total of 150 patients were evaluated in this study. The main 
health problems at ICU admission were respiratory problems, 
such as respiratory infection or airway obstruction, in 71 patients 
(47%); neurologic problems, such as status epilepticus or brain 
hemorrhage, in 31 patients (21%); gastrointestinal problems, 
such as gastrointestinal bleeding or fulminant hepatitis, in 9 pa-
tients (6%); nephrogenic problems, such as renal failure, in 10 
patients (7%); hemato-oncologic problems, such as tumor lysis 
syndrome or neutropenic fever during chemotherapy, in 16 pa-
tients (10%); metabolic disorders in 4 patients (3%); postopera-
tive care in 6 patients (4%); and other problems in 3 patients (2%).
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Clinical characteristics of the survivor and non-survivor 
groups
The ICU mortality rate was 21% (n = 31). The primary health prob-
lems at the time of ICU admission in the non-survivor group 
were respiratory problems in 11 patients (35%), neurologic prob-
lems in 7 patients (23%), gastrointestinal problems in 3 patients 
(10%), nephrogenic problems in 3 patients (10%), hemato-on-
cologic problems in 5 patients (16%), and metabolic disorders 
in 2 patients (6%). Clinical characteristics, PICU mortality scores, 
and laboratory data were compared between the survivor and 
non-survivor groups (Table 1). PICU mortality scores were sig-
nificantly higher, while eosinophil counts, eosinophil percent-
ages, and platelet counts were significantly lower in the non-sur-
vivor groups. There was no significant difference in infection 
status or mechanical ventilation rate between the groups. With 
regard to the other laboratory data, CRP, WBC, neutrophil count, 
and neutrophil percentage were not statistically different.
Clinical characteristics of the non-infection and infection 
groups
At the time of admission, 103 patients (69%) were classified into 
the infection group. The sites of infection were the respiratory 
tract in 68 patients (66%), central nervous system in 13 patients 
(13%), gastrointestinal tract in 6 patients (6%), urinary tract in 4 
patients (4%), and other locations in 12 patients (11%). Clinical 
characteristics, PICU mortality scores, and laboratory data were 
compared between the non-infection group and the infection 
group in Table 2. Among the patients who survived, those with 
infection stayed longer in the ICU than those without. There was 
no statistically significant difference in age, sex, survival rate, or 
PRISM III, PIM 2 and PELOD scores. In terms of laboratory data, 
eosinophil count and eosinophil percentage were not statisti-
cally different.
Eosinophil count and eosinophil percentage in predicting 
ICU mortality
We tested the diagnostic performance of eosinophil count and 
Table 1. Clinical characteristics, PICU mortality scores, and laboratory data between the survivor and non-survivor groups
Parameters Survivor (n = 119) Non-survivor (n = 31) P  value
Age (yr) 3.2 (0.9-9.7) 3.1 (1.1-8.4) 0.926
Male sex, No (%) 73 (61) 22 (71) 0.322
Infection case, No (%) 84 (71) 19 (61) 0.320
Mechanical ventilation, No (%) 67 (56) 23 (74) 0.070
PRISM III score 8.0 (5.0-11.0) 15.0 (9.0-17.0) < 0.001
PIM 2 score 3.3 (1.4-7.1) 26.6 (6.4-51.6) < 0.001
PELOD score 2.0 (1.0-12.0) 12.0 (10.0-22.0) < 0.001
C-reactive protein (mg/dL) 7.07 (2.10-45.50) 11.20 (4.48-72.91) 0.468
WBC (cells/µL) 11,590 (5,795-20,670) 11,310 (9,033-21,950) 0.492
Neutrophil (cells/µL) 6,170 (3,545-13,675) 9,050 (4,990-13,625) 0.772
Neutrophil (% of WBC) 64.5 (55.1-83.8) 66.6 (43.9-85.4) 0.508
Eosinophil (cells/µL) 80.0 (30.0-204.5) 45.0 (0-72.5) < 0.001
Eosinophil (% of WBC) 0.60 (0.25-1.65) 0.20 (0.00-0.70) < 0.001
Platelet (103/µL) 288.0 (165.0-431.5) 217.0 (89.3-380.3) 0.011
PICU, pediatric intensive care unit; PRISM, pediatric risk of mortality; PIM, pediatric index of mortality; PELOD, pediatric logistic organ dysfunction, WBC, white blood cell.
Table 2. Clinical characteristics, PICU mortality scores, and laboratory data between the non-infection and infection groups
Parameters Non-infection (n = 47) Infection (n = 103) P  value
Age (yr) 3.2 (0.6-10.1) 2.9 (1.1-8.3) 0.985
Male sex, No (%) 34 (72) 61 (59) 0.122
Survivor case, No (%) 35 (75) 84 (82) 0.320
ICU length in survivors (days) 5.0 (3.0-13.0) 8.0 (5.0-15.0) 0.016
PRISM III score 11.0 (5.0-16.0) 8.0 (5.0-12.0) 0.109
PIM 2 score 6.8 (1.9-13.8) 3.9 (1.5-9.1) 0.090
PELOD score 11.0 (1.0-20.0) 10.0 (1.0-12.0) 0.216
C-reactive protein (mg/dL) 6.35 (1.76-24.92) 11.50 (2.59-57.89) 0.355
WBC (cells/µL) 11,190 (6,345-22,725) 11,500 (6,775-20,110) 0.471
Neutrophil (cells/µL) 6,670 (3,545-18,395) 6,620 (4,125-13,100) 0.870
Neutrophil (% of WBC) 65.1 (54.9-81.9) 64.4 (52.9-85.5) 0.247
Eosinophil (cells/µL) 85.0 (30.0-215.0) 60.0 (20.0-185.0) 0.882
Eosinophil (% of WBC) 0.75 (0.28-2.00) 0.50 (0.20-1.25) 0.981
Platelet (103/µL) 238.0 (160.3-405.8) 296.0 (159.5-425.5) 0.657
PICU, pediatric intensive care unit; PRISM, pediatric risk of mortality; PIM, pediatric index of mortality; PELOD, pediatric logistic organ dysfunction, WBC, white blood cell.
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eosinophil percentage taken at the time of ICU admission. The 
areas under the ROC curves of the eosinophil count and eosin-
ophil percentage used to distinguish between the survivor and 
non-survivor groups were 0.705 (P < 0.001) and 0.725 (P < 0.001), 
respectively (Fig. 1). The best eosinophil count and eosinophil 
percentage cutoff values were 15 cells/µL and 0.25%, respec-
tively. At the cutoff of 15 cells/µL, the sensitivity of the eosino-
phil count was 48.4%, the specificity was 84.9%, and the AUC 
was 0.667. At the cutoff of 0.25%, the sensitivity of the eosinophil 
percentage was 58.1%, the specificity was 76.5%, and the AUC 
was 0.673. When we considered both the eosinophil count and 
percentage together, both the specificity and the AUC increased 
to 92.4% and 0.732, respectively, while the sensitivity remained 
at 58.1%.
 Since the platelet count at the time of ICU admission was sig-
nificantly lower in non-survivors than in survivors, we also gen-
erated a ROC curve for the platelet count. We determined that 
the best cutoff value for platelet count (90 × 103/µL) resulted in 
an AUC of 0.614, with a sensitivity of 38.7% and a specificity of 
84.0%. 
 At ICU admission, the children with eosinopenia (eosinophil 
count < 15 cells/µL and an eosinophil percentage < 0.25%) 
had a significantly lower survival rate, as determined by the log-
rank test and the Kaplan-Meier survival curves (P < 0.001) (Fig. 
2). Univariate analysis utilizing the Cox regression model revealed 
that eosinopenia (HR, 4.34; P < 0.001), PRISM III (HR, 1.13; P <  
0.001), PIM 2 (HR, 1.03; P < 0.001), PELOD (HR, 1.08; P < 0.001), 
mechanical ventilator (HR, 2.03; P = 0.084), and platelet count 
< 90 × 103/µL (HR, 2.93; P = 0.004) were correlated with ICU 
mortality. In multivariate analysis, only eosinopenia (HR, 2.96; 
P = 0.008) and PIM 2 (HR, 1.03; P = 0.004) were found to be in-
dependent predictors of ICU mortality (Table 3).
DISCUSSION
This is the first study to assess eosinopenia at the time of ICU 
admission as a prognostic biomarker in children. This study sug-
gests that, along with PIM 2, eosinopenia is a reliable marker 
that is able to predict ICU mortality in children. However, it was 
not found to be valuable in diagnosing infection at PICU admis-
sion.
 A prognostic biomarker of mortality is currently needed be-
cause the prediction of mortality would enable physicians to 
make better treatment decisions (9). Until now, the most accept-
able way to predict mortality in the ICU is through the use of a 
composite scoring system that consists of mainly physiologic 
variables. In the PICU, PRISM III and PIM 2 are frequently used 
as scoring systems to predict the severity of illness at the time of 
Table 3. Multivariate analysis using Cox model of prognosis markers of mortality in 
the PICU
Variables Hazard ratio
95% Confidence 
interval
P  value
Eosinopenia 2.96 1.33-6.61 0.008
PRISM III score 1.04 0.97-1.12 0.225
PIM 2 score 1.03 1.01-1.04 0.004
PELOD score 0.99 0.94-1.05 0.835
Mechanical ventilation 1.65 0.63-4.31 0.310
Platelet < 90 × 103/µL 1.99 0.89-4.46 0.096
PICU, pediatric intensive care unit; PRISM, pediatric risk of mortality; PIM, pediatric 
index of mortality; PELOD, pediatric logistic organ dysfunction.
Fig. 1. Receiver operating curves (ROC) of eosinophil counts and eosinophil percent-
ages used to distiguish survivors from non-survivors. The area under the curve is 0.705 
for eosinophil count (P < 0.001) and 0.725 for eosinophil percentage (P < 0.001).
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Fig. 2. Survival curves for the children with eosinopenia and without eosinopenia. The 
eosinopenia was defined by an eosinophil count < 15 cells/µL and an eosinophil per-
centage < 0.25% (P < 0.001 by log-rank test).
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ICU admission, while PELOD is used for serial measurements 
during the length of the ICU stay (2). In this study, the utility of 
the PICU mortality score in predicting ICU mortality was veri-
fied. Specifically, PIM 2 was an independent predictor even af-
ter adjustment for other factors (Table 3).
 Thrombocytopenia has been accepted as a useful prognostic 
factor in children as well as in adults, which was further sup-
ported in our study (18). Thrombocytopenia serves as a reason-
able predictor of mortality both because it develops from a seri-
ously impaired condition and it may lead to a more severe situ-
ation, such as increased bleeding and transfusion requirements 
(18, 19).
 Our study demonstrated that eosinophil counts and eosino-
phil percentages were significantly lower in non-surviving chil-
dren, which is similar to prior studies performed in adults (10, 
11). While the most acceptable cutoff for the eosinophil count 
in adults as a predictor of mortality is 40-50 cells/µL (10, 11, 20), 
our study suggested a lower level of 15 cells/µL in pediatric pa-
tients. This lower value can potentially be explained by either 
the greater vulnerability of children during severe inflamma-
tion and stress or the greater proportion of children who were 
medical, rather than surgical, ICU patients (medical vs surgical 
patients: 144 [95%] vs 6 [5%]) (21).
 While most studies addressed only absolute eosinophil count 
(10, 11), our study evaluated both eosinophil count and percent-
age. When the eosinophil count and percentage were consid-
ered together, the predictive power for ICU mortality increased, 
with higher values for both the specificity and the AUC. Consid-
ering the fact that specificity might be more informative than 
sensitivity for the prediction of mortality (9), this combination 
may be more reasonable. The children with eosinopenia who 
had an eosinophil count < 15 cells/µL and an eosinophil per-
centage < 0.25% had a lower rate of survival (Fig. 2). Eosinope-
nia increased the risk of mortality by a HR of 2.96 according to 
multivariate analysis using a Cox regression model (Table 3).
 Eosinopenia has been studied as an infection biomarker. How-
ever, our study showed that it was not useful in the prediction of 
infection status. The median eosinophil count and eosinophil 
percentage were lower in the infection group than in the non-
infection group, but the difference was not statistically signifi-
cant (Table 2). There are several studies that illustrate the value 
of eosinopenia in children suffering from infectious diseases, 
while another study concluded that eosinopenia was of limited 
use as a biomarker in pediatric patients with infections (22-24). 
On the other hand, eosinopenia has been consistently consid-
ered a useful diagnostic marker of infection in adults (25, 26). 
The greater ambiguity in the signs and symptoms of infection in 
children might contribute to the difference seen between adults 
and children. A shorter prodrome in children, which may not 
be long enough to decrease the level of eosinophils, can also 
explain this difference (24).
 Eosinopenia is more representative of mortality than of an 
infection because it can develop from acute infection or acute, 
severe stress, both of which are strongly correlated with mortality 
(12, 13, 15). Infection is known to be the most common cause of 
ICU mortality (12). However, infection status alone is not enough 
to predict ICU mortality. Recently, many clinics have been try-
ing to initially control infection, emphasizing early antimicrobi-
al therapy (27). The study at our center demonstrated that there 
was no difference in the survival rate or pediatric mortality scores 
based upon the infectious status (Table 2). Nonetheless, the chil-
dren with infections had longer ICU courses than the children 
without infections amongst the surviving cases. Although infec-
tion status may not directly relate to ICU mortality, it can affect 
the clinical course in the ICU.
 The limitations of this study should be considered. First, this 
was a single-center study, which excluded infant and cardiac 
cases and included limited surgical cases. Therefore, our con-
clusions cannot be generalized to all PICU patients. Second, we 
should have evaluated the serial change in eosinophil counts 
and percentages for a certain period of time after ICU admission. 
Since many of the children were treated with systemic cortico-
steroids after ICU admission, we were unable to evaluate serial 
changes. Third, the infection group was defined according to 
the International Pediatric Sepsis Consensus Conference in our 
study, while it was classified as sepsis or bloodstream infection 
in most other studies (17, 24-26). Because sepsis is a SIRS asso-
ciated with an infection, it can induce a more severe systemic 
inflammation than infection without SIRS. Thus, the level of eo-
sinopenia in our study might have been underestimated.
 In conclusion, eosinopenia in the PICU can be useful as a 
mortality biomarker, but not as an infection biomarker. Eosino-
penia (eosinophil count < 15 cells/µL and eosinophil percent-
age < 0.25%) can increase the risk of ICU mortality in children 
and may help ICU pediatricians determine the right treatment 
plan, in conjunction with other pediatric mortality scoring sys-
tems.
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